Document is current
Any future updates will be listed below
-
Authors
Ali, M. Sanni
Stockdale, Lisa
Sagara, Issaka
Zongo, Issaka
Yerbanga, Rakiswendé Serge
Mahamar, Almahamoudou
Nikièma, Frédéric
Tapily, Amadou
Sompougdou, Frédéric
Diarra, Modibo
Bellamy, Duncan
Provstgaard-Morys, Samuel
Zoungrana, Charles
Issiaka, Djibrilla
Haro, Alassane
Sanogo, Koualy
Sienou, Abdoul Aziz
Kaya, Mahamadou
Traore, Seydou
Dicko, Oumar M.
Kone, Youssouf
Yalcouye, Hama
Thera, Ismaila
Diarra, Kalifa
Snell, Paul
Ofori-Anyinam, Opokua
Ockenhouse, Chris
Lee, Cynthia
Ewer, Katie
Tinto, Halidou
Djimde, Abdoulaye
Ouedraogo, Jean-Bosco
Dicko, Alassane
Chandramohan, Daniel
Greenwood, Brian
-
Funding
Funding for this research was provided by:
UK Joint Global Health Trials (MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1, MR/V005642/1)
PATH MVI (INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217, INV-007217)
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 24 January 2025
First Online: 6 February 2025
Competing interests
: O.O. and K.E. are employees of the GSK group of companies and have restricted shares in the GSK group of companies. K.E. is a named inventor on patents relating to the R21/matrix M vaccine. A Dicko. reports a research grant from Grand Challenges Canada to test safety and efficacy of the PfSPZ vaccine for pregnant women and unborn children and a research contract with Oxford University to conduct a phase 3 randomized, controlled multicentre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria outside of the submitted work. All other authors report no potential conflicts.
